Search research articles
Contact Us
Filters
Showing results (301-310 of 303) with videos related to
Page
of 31
Sort By:
You have reached the last page of results.
This site can display upto 303 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 20, 2026
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer
A C Garrido-Castro, S E Kim, T Li, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 6, 2007
Guidelines on the standards for the training of specialised health professionals dealing with breast cancer
L Cataliotti, C De Wolf, R Holland, et al.
Micropublication Biology
|
January 21, 2021
<i>B.2.16</i> is a non-lethal modifier of the <i>Dark</i> mosaic eye phenotype in <i>Drosophila melanogaster</i>
Alysia D Vrailas-Mortimer, Nitish Aggarwal, Neha N Ahmed, et al.
Page
of 31
Search research articles
Search
Showing results (301-310 of 303) with videos related to
Sort By:
Page
of 31
You have reached the last page of results.
This site can display upto 303 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 20, 2026
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer
A C Garrido-Castro, S E Kim, T Li, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 6, 2007
Guidelines on the standards for the training of specialised health professionals dealing with breast cancer
L Cataliotti, C De Wolf, R Holland, et al.
Micropublication Biology
|
January 21, 2021
<i>B.2.16</i> is a non-lethal modifier of the <i>Dark</i> mosaic eye phenotype in <i>Drosophila melanogaster</i>
Alysia D Vrailas-Mortimer, Nitish Aggarwal, Neha N Ahmed, et al.
Page
of 31